Long-term anticholinergic use and the aging brain

Alzheimer's and Dementia

Volumn 9, Issue 4, 2013, Pages 377-385

  Cai, Xueya ^a   Campbell, Noll ^b,c,d,e   Khan, Babar ^f   Callahan, Christopher ^b,c,f   Boustani, Malaz ^b,c,f  

^a UNIVERSITY OF IOWA   (United States)

^b REGENSTRIEF INSTITUTE   (United States)

^c INDIANA UNIVERSITY CENTER FOR AGING RESEARCH   (United States)

^d PURDUE UNIVERSITY   (United States)

^e WISHARD HEALTH SERVICES   (United States)

^f INDIANA UNIVERSITY   (United States)

Author keywords

Anticholinergics; Cognitive impairment; Dementia; Elderly; Mild cognitive impairment

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT;

AGED; ANTICHOLINERGIC COGNITIVE BURDEN LIST; ARTICLE; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84882449192     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.02.005     Document Type: Article

References (32)

1. United States Census Bureau. Available at: Http://www.census.gov/Press- Release/www/releases/archives/population/006808.html.
2. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions of the elderly. Arch Intern Med 2002;162:2269-76.
3. Schubert CC, Boustani M, Callahan CM, Perkins AJ, Carney CP, Fox C, et al. Comorbidity profile of dementia patients in primary care: Are they sicker? J Am Geriatr Soc 2006;54:104-9.
4. Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. U.S. Preventive Services Task Force Screening for dementia in primary care: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003;138:927-37.
5. Boustani M, Campbell, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: A review and practical application. Aging Health 2008;4:311-20.
6. Bottigi KA, Salazar JC, Yu L, Caban-Holt AM, Ryan M, Mendiondo MS, et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry 2006;14:980-4.
7. Campbell N, Limbil T, Boustani M, Ott C, Fox C, Maidment I, et al. The cognitive impact of anticholinergics: A clinical review. Clin Interv Aging 2009;4:225-33.
8. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Rithie K. Nondegenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study. BMJ 2006; 332:455-9.
9. Roe C, Anderson M, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 2002;50:836-42.
10. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008;56:2203-10.
11. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003;54:235-8.
12. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, et al. M1 receptors play a central role in modulating ADlike pathology in transgenic mice. Neuron 2006;49:671-82.
13. Haring R, Fisher A, Marciano D, Pittel Z, KloogY, Zuckerman A, et al. Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to b-amyloid protein secretion. J Neurochem 1998;71:2094-103.
14. Jedrziewski MK, Lee VM-Y, Trojanowski JQ. Lowering the risk of Alzheimer's disease: Evidence-based practices emerge from new research. Alzheimers Dement 2005;1:152-60.
15. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
16. Carriere I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-city study. Arch Intern Med 2009;169:1317-24.
17. McDonald CJ, Overhage JM, Tierney WM, Dexter PR, Martin DK, Suico JG, et al. The Regenstrief Medical Record System: A quarter century experience. Int J Med Inform 1999;54:225-53.
18. Boustani M, Callahan CM, Unverzagt FW, Austrom MG, Perkins AJ, Fultz BA, et al. Implementing a screening and diagnosis program for dementia in primary care. J Gen Intern Med 2005;20:572-7.
19. Boustani M, Perkins AJ, Fox C, Unverzagt F, Austrom MG, Fultz B, et al. Who refuses dementia assessment in primary care? Int J Geriatr Psychiatry 2006;21:556-63.
20. Callahan CM, Boustani MA, Unverzagt FW, Austrom MG, Damush TM, Perkins AJ, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: A randomized controlled trial. JAMA 2006;295:2148-57.
21. Stroupe KT, Murray MD, Stump TE, Callahan CM. Association between medication supplies and healthcare costs in older adults from an urban healthcare system. J Am Geriatr Soc 2000;48:760-8.
22. Fisch M, Callahan CM, Kesterson JG, Nichols C, Tierney WM. The use of an electronic patient record system to identify advanced cancer patients and antidepressant drug use. J Palliat Med 1999; 2:403-9.
23. Callahan CM, Unverzagt FW, Hui SL, Perkins AJ, Hendrie HC. Sixitem screener to identify cognitive impairment among potential subjects for clinical research. Med Care 2002;40:771-81.
24. Hall KS, Ogunniyi AO, Hendrie HC, Osuntokun BO, Hui SL, Musick BS, et al. A cross-cultural community based study of dementias: Methods and performance of the survey instrument Indianapolis, USA, and Ibadan, Nigeria. Int J Meth Psychiatr Res 1996; 6:129-42.
25. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 1988;24:641-52.
26. ICD-10. The International Statistical Classification of Diseases and Related Health Problems: 1 and 2. Report number: V.3. Washington, DC: American Psychiatric Association Press; 1992.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed, Revised. Washington, DC: American Psychiatric Association; 1987.
28. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60:616-31.
29. Fox C, Richardson K, Maidment I, Smithard D, Katona C, Livingston G, et al., the MRC-CFAS. Anticholinergic medication use and cognitive impairment in the older population. The Medical Research Council Cognitive Function and Ageing Study. JAm Geriatr Soc 2011;59:1477-83. 10.1111/j.1532-5415.2011.03491.x.
30. Campbell NL, Boustani MA, Lane KA, Gao S, Hendrie H, Khan BA, et al. Use of anticholinergics and the risk of cognitive impairment in an African-American population. Neurology 2010; 75:152-9.
31. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999;37:846-57.
32. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-74.